LivaNova PLC (NASDAQ:LIVN) Receives Consensus Recommendation of "Buy" from Analysts

Key Points

• LivaNova PLC has received a consensus rating of "Buy" from analysts, with the average 12-month price objective set at approximately $59.71.
• Several analysts have recently raised their price targets for LivaNova, with estimates ranging from $58.00 to $64.00, reflecting positive sentiment towards the stock.
• The company reported earnings of $1.05 per share for the last quarter, surpassing estimates and showcasing a 10.6% revenue increase from the previous year.

Shares of LivaNova PLC (NASDAQ:LIVN - Get Free Report) have earned an average rating of "Buy" from the eight ratings firms that are presently covering the company, Marketbeat reports. One research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $59.7143.

A number of analysts have recently weighed in on LIVN shares. Barclays upped their price objective on LivaNova from $55.00 to $58.00 and gave the stock an "equal weight" rating in a research report on Thursday, August 21st. Wall Street Zen raised LivaNova from a "buy" rating to a "strong-buy" rating in a research report on Saturday, August 9th. Needham & Company LLC reaffirmed a "buy" rating and set a $64.00 price objective on shares of LivaNova in a research report on Wednesday. Finally, Wolfe Research raised LivaNova from a "peer perform" rating to an "outperform" rating and set a $60.00 price objective on the stock in a research report on Tuesday, May 20th.

Institutional Investors Weigh In On LivaNova

Several institutional investors have recently modified their holdings of the company. Invesco Ltd. raised its stake in LivaNova by 714.7% during the 2nd quarter. Invesco Ltd. now owns 1,028,713 shares of the company's stock worth $46,313,000 after acquiring an additional 902,447 shares in the last quarter. AQR Capital Management LLC raised its stake in LivaNova by 111.7% during the 1st quarter. AQR Capital Management LLC now owns 1,571,295 shares of the company's stock worth $60,809,000 after acquiring an additional 829,115 shares in the last quarter. Scopia Capital Management LP acquired a new stake in LivaNova during the 2nd quarter worth $36,657,000. Nuveen LLC acquired a new stake in LivaNova during the 1st quarter worth $30,954,000. Finally, Artisan Partners Limited Partnership raised its stake in LivaNova by 112.9% during the 2nd quarter. Artisan Partners Limited Partnership now owns 1,247,609 shares of the company's stock worth $56,167,000 after acquiring an additional 661,480 shares in the last quarter. 97.64% of the stock is owned by hedge funds and other institutional investors.

LivaNova Trading Down 0.3%

Shares of NASDAQ:LIVN traded down $0.18 during mid-day trading on Thursday, reaching $57.97. 958,459 shares of the company were exchanged, compared to its average volume of 633,219. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.29 and a quick ratio of 1.09. The firm has a market cap of $3.17 billion, a price-to-earnings ratio of -14.90 and a beta of 0.97. The firm's 50-day simple moving average is $48.67 and its 200 day simple moving average is $43.68. LivaNova has a 1 year low of $32.48 and a 1 year high of $58.42.

LivaNova (NASDAQ:LIVN - Get Free Report) last issued its quarterly earnings results on Wednesday, August 6th. The company reported $1.05 EPS for the quarter, beating the consensus estimate of $0.84 by $0.21. LivaNova had a negative net margin of 16.13% and a positive return on equity of 14.57%. The company had revenue of $352.50 million during the quarter, compared to analysts' expectations of $332.20 million. During the same quarter last year, the company posted $0.93 EPS. The firm's revenue was up 10.6% compared to the same quarter last year. Equities research analysts forecast that LivaNova will post 2.85 EPS for the current year.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.